Hib-DTaP-Hepatitis-B-Poliovirus vaccine - Sanofi
Alternative Names: 6-in-1 paediatric vaccine - Sanofi; DTaP-IPV-HB-PRP-T; DTaP-IPV-Hep B-PRP-T; DTaP-IPV-Hib-HepB vaccine - Sanofi; DTaP2-IPV-Hep B-PRP-T - Sanofi; DTwP-HepB-Hib-IPV vaccine - Sanofi; Hexacima; Hexaxim; HexyonLatest Information Update: 05 Nov 2023
At a glance
- Originator sanofi pasteur
- Developer Sanofi Pasteur
- Class Haemophilus vaccines; Hepatitis B vaccines; Vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Diphtheria; Haemophilus infections; Hepatitis B; Pertussis; Poliomyelitis; Tetanus
Most Recent Events
- 22 Feb 2019 Sanofi Pasteur completes a phase III trial for Diphtheria/Tetanus/Pertussis/Hepatitis B/Poliomyelitis/Haemophilus infections (In infants, Prevention) in South Africa (IM) (NCT02817451)
- 30 Apr 2018 Sanofi Pasteur completes a phase I/II trial for Diphtheria/Tetanus/Pertussis/Hepatitis B/Poliomyelitis/Haemophilus infections (In infants, Prevention) in India (IM) (CTRI2016-11-007434)
- 02 Jan 2017 Sanofi Pasteur MSD ended their joint venture and will separately pursue their vaccine strategies in Europe